BofA analyst initiates coverage of iRhythm with a Buy rating and $200 price target

BofA analyst Stephanie Piazzola initiated coverage of iRhythm (IRTC) with a Buy rating and a $200 price target. The analyst's initiation of coverage is a positive development for the company and could lead to increased investor interest and potential price appreciation.

BofA analyst Stephanie Piazzola has initiated coverage on iRhythm Technologies, Inc. (IRTC) with a Buy rating and a $200 price target. This positive development is likely to attract increased investor interest and potentially drive price appreciation for the company.

iRhythm, a leading provider of wireless patch-based sensors for long-term continuous monitoring of electrocardiogram (ECG) data, has been recognized for its innovative Zio service. The Zio service is considered "best in class" for diagnosing arrhythmias, which can cause strokes and heart failure if left untreated. The analyst at BofA highlights the company's market expansion efforts with primary care physicians and asymptomatic patients, as well as its potential to achieve EBITDA profitability.

The analyst's positive stance is supported by recent real-world evidence studies. A large-scale study published in the American Journal of Managed Care found that iRhythm's Zio LTCM service outperformed other monitoring approaches in terms of diagnostic yield, time to diagnosis, cardiovascular events, and total healthcare costs. This study, which included over 428,000 commercially insured patients, reinforced the clinical superiority of the Zio LTCM service across various patient populations and payer segments [2].

The findings from this study are consistent with previous research, which demonstrated the Zio LTCM service's clinical advantages among a Medicare patient population. The latest study extends these findings to a younger, commercially insured population, further solidifying iRhythm's position as a leader in ambulatory cardiac monitoring.

Investors should closely monitor iRhythm's progress as it continues to expand its market presence and improve its profitability. The company's innovative technology and strong clinical evidence position it well for future growth.

References:
[1] https://www.tipranks.com/news/the-fly/irhythm-initiated-with-a-buy-at-bofa-on-market-and-margin-expansion-thefly
[2] https://www.morningstar.com/news/globe-newswire/9513859/avalon-real-world-evidence-builds-on-camelot-study-reinforcing-irhythms-zio-ltcm-clinical-superiority